← board
CINGW
distress 8/10 · high distress / dilution risk$0.02-67%today-67% from 52w high
Lead: ADHD
Revenue
pre-revenue
Liquidity
$26M
Runway
1.3 yrs
Shares 1y
+145%
Price & events
-54.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-66.7%
1D
-14.2%
1W
-66.7%
1M
-66.7%
3M
—
6M
—
1Y
—
2Y
—
5Y
-54.4%
All
Overview
- Market Cap
- $265.52K
- Volume
- 218
- 52 Week Range
- $0.02 – $0.06
- Total Shares
- 13.28M
- Float Shares
- 12.94M
- RVOL
- 2.29x
- Beta
- -0.92
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- May 31, 2026PDUFAPDUFACTx-1301 · PDUFA target action date for NDA review.SEC 8-K
- July 31, 2025regulatory submissionFiled (NDA/BLA)CTx-1301 · NDA submitted to FDA for CTx-1301SEC 8-K
- mid-2025regulatory submissionFiled (NDA/BLA)CTx-1301 · NDA submission for CTx-1301SEC 8-K
- mid-2025readoutPhase 3CTx-1301 · Final combined safety and efficacy analysisSEC 8-K
- 2025-04-08partnershipCTx-2103 · Received $3M grant from private foundation; $1M on May 1, 2025, remainder upon milestones.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — ADHD
Recent news
- 2026-07-01Cingulate Inc. (CING) Surges 8.78% as Momentum Builds Near Key Resistance Level - Price Momentum Stocks - dars.gov.et
- 2026-06-17Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- 2026-06-17Cingulate Inc. Warrants (CINGW) Rallies 35% to $0.03 Amid Speculative Trading - Quality ETF - dars.gov.et
- 2026-06-16Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - The Manila Times
- 2026-06-10Cingulate Inc. Warrants (CINGW) Narrows to Key Level: A Tight Trading Range Emerges - AAII Bearish - dars.gov.et
- 2026-06-07Cingulate Inc. Warrants (CINGW) Face Continued Pressure as Shares Test Penny Levels - Volatility Smirk - dars.gov.et
- 2026-06-02Cingulate stock tumbles after FDA issues response letter By Investing.com - Investing.com UK
- 2026-05-31Cingulate Nears FDA Verdict on ADHD Drug Amid Manufacturing Hurdles - BriefGlance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.